Pagani et al. reported the results of asciminib treatment in a CML patient with an atypical e19a2 BCR::ABL1 transcript, who had previously developed a T315I kinase domain mutation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.